OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-1.03%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.28%
AUM
$438M
AUM Growth
+$438M
(-4.6%)
Cap. Flow
+$11.6M
Cap. Flow
% of AUM
2.65%
Top 10 Holdings %
Top 10 Hldgs %
58.99%
Holding
62
New
9
Increased
15
Reduced
17
Closed
11
Top Buys
| 1 |
Immunome
IMNM
|
$13.3M |
| 2 |
Cytokinetics
CYTK
|
$10.8M |
| 3 |
CRGX
CARGO Therapeutics
CRGX
|
$9.12M |
| 4 |
Arvinas
ARVN
|
$5.99M |
| 5 |
Biodesix
BDSX
|
$5.33M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$9.83M |
| 2 |
Ocular Therapeutix
OCUL
|
$9.2M |
| 3 |
Compass Therapeutics
CMPX
|
$6.28M |
| 4 |
Catalyst Pharmaceutical
CPRX
|
$5.64M |
| 5 |
NYXH
Nyxoah
NYXH
|
$4.32M |
Sector Composition
| 1 | Healthcare | 98.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Protara Therapeutics
TARA
$125M
| $5.3M | 1.21% |
2,304,262
-388,332
| -14% | -$893K |
|
27
Intellia Therapeutics
NTLA
$1.26B
| $4.88M | 1.11% |
218,000
-37,000
| -15% | -$828K |
|
28
Nuvalent
NUVL
$5.74B
| $4.5M | 1.03% |
+59,300
| New | +$4.5M |
|
|
SYRS
29
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4.47M | 1.02% |
865,443
+77,898
| +10% | +$402K |
|
30
Liquidia Corp
LQDA
$2.52B
| $3.9M | 0.89% |
325,000
-70,000
| -18% | -$840K |
|
31
Protagonist Therapeutics
PTGX
$3.62B
| $3.64M | 0.83% |
105,000
-7,700
| -7% | -$267K |
|
32
Gossamer Bio
GOSS
$587M
| $3.52M | 0.8% |
3,910,000
+1,469,891
| +60% | +$1.32M |
|
33
Lexicon Pharmaceuticals
LXRX
$392M
| $3.15M | 0.72% |
+1,875,000
| New | +$3.15M |
|
34
Savara
SVRA
$591M
| $2.88M | 0.66% |
714,960
-140,040
| -16% | -$564K |
|
|
ALLK
35
DELISTED
Allakos
ALLK
| $2.78M | 0.64% |
2,780,000
+345,000
| +14% | +$345K |
|
36
Ventyx Biosciences
VTYX
$184M
| $2.75M | 0.63% |
1,190,000
-95,000
| -7% | -$219K |
|
37
Verastem
VSTM
$585M
| $2.73M | 0.62% |
915,000
+703,600
| +333% | +$2.1M |
|
|
RGLS
38
DELISTED
Regulus Therapeutics
RGLS
| $2.63M | 0.6% |
1,475,000
+1,304,692
| +766% | +$2.33M |
|
39
Lyell Immunopharma
LYEL
$220M
| $2.42M | 0.55% |
1,670,000
-1,685,000
| -50% | -$2.44M |
|
40
Relmada Therapeutics
RLMD
$48.8M
| $1.8M | 0.41% |
600,000
-159,000
| -21% | -$477K |
|
41
Fulcrum Therapeutics
FULC
$353M
| $1.77M | 0.4% |
285,000
+155,000
| +119% | +$961K |
|
42
Karyopharm Therapeutics
KPTI
$61.4M
| $1.24M | 0.28% |
+1,425,000
| New | +$1.24M |
|
43
iBio
IBIO
$16.9M
| $791K | 0.18% |
375,000
-305,000
| -45% | -$644K |
|
44
PMV Pharmaceuticals
PMVP
$82.1M
| $770K | 0.18% |
475,000
+3,519
| +0.7% | +$5.7K |
|
|
JBIO
45
Jade Biosciences, Inc. Common Stock
JBIO
$245M
| $730K | 0.17% |
+440,000
| New | +$730K |
|
46
Design Therapeutics
DSGN
$339M
| $687K | 0.16% |
205,000
+91,962
| +81% | +$308K |
|
47
AbCellera Biologics
ABCL
$1.19B
| $592K | 0.14% |
+200,000
| New | +$592K |
|
48
Aligos Therapeutics
ALGS
$75.1M
| $441K | 0.1% |
1,260,000
-370,000
| -23% | -$130K |
|
|
OKUR
49
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$38.3M
| $249K | 0.06% |
+165,000
| New | +$249K |
|
|
MOR
50
DELISTED
MorphoSys AG American Depositary Shares
MOR
| – | – |
-65,000
| Closed | -$1.18M |
|